BCL2 and prostate cancer: Interestingly, a recent epidemiological study has showed that, naftopidil, a naphthalene-based α1-adrenoceptor antagonist, reduces prostate cancer incidence due to its blocking effect on TGF-β signaling and Bcl-2 expression 60, which is consistent with our finding that lower levels of TGF-β signaling and Bcl-2 expression correlated with prolonged disease free survival in patients with advanced prostate cancer.